These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 7765395)
1. Anti-bacterial antibodies in Epstein-Barr virus (EBV)-transformed oligoclonal B-cell lines established from normal persons and autoimmune disease patients. Nagatsuka Y; Hanazawa S; Koroiwa Y; Fukuda T; Suganuma T; Ono Y Lett Appl Microbiol; 1994 Oct; 19(4):206-9. PubMed ID: 7765395 [TBL] [Abstract][Full Text] [Related]
2. Anti-glycolipid antibodies produced by Epstein-Barr virus (EBV)-transformed oligoclonal B cell lines obtained from normal persons and autoimmune disease patients. Nagatsuka Y; Hanazawa S; Yasuda T; Ono Y Hum Antibodies Hybridomas; 1994; 5(3-4):183-6. PubMed ID: 7756582 [TBL] [Abstract][Full Text] [Related]
3. Effect of Interleukins on Antibody Production by Epstein-Barr Virus Transformed B Cells. Ali AI; Badran YR; Hassuneh MR; Sanber KS; Ismail SI Monoclon Antib Immunodiagn Immunother; 2015 Jun; 34(3):162-8. PubMed ID: 26090593 [TBL] [Abstract][Full Text] [Related]
4. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases. Niller HH; Wolf H; Minarovits J Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410 [TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus-carrying B cells in the blood during acute infectious mononucleosis give rise to lymphoblastoid lines in vitro by release of transforming virus and by proliferation. Lewin N; Aman P; Akerlund B; Gustavsson E; Carenfelt C; Lejdeborn L; Klein G; Klein E Immunol Lett; 1990 Oct; 26(1):59-65. PubMed ID: 2177451 [TBL] [Abstract][Full Text] [Related]
6. Human monoclonal antibodies to Pseudomonas aeruginosa produced by EBV-transformed cells. Suzuki H; Okubo Y; Moriyama M; Sasaki M; Matsumoto Y; Hozumi T Microbiol Immunol; 1987; 31(10):959-66. PubMed ID: 2828894 [TBL] [Abstract][Full Text] [Related]
7. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells. Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009 [TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr Virus Lytic Reactivation Induces IgG4 Production by Host B Lymphocytes in Graves' Disease Patients and Controls: A Subset of Graves' Disease Is an IgG4-Related Disease-Like Condition. Nagata K; Hara S; Nakayama Y; Higaki K; Sugihara H; Kuwamoto S; Matsushita M; Kato M; Tanio S; Ishiguro K; Hayashi K Viral Immunol; 2018 Oct; 31(8):540-547. PubMed ID: 30222515 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms other than polyclonal B cell activation possibly involved in Epstein-Barr virus-induced autoimmunity. Garzelli C; Pacciardi A; Basolo F; Falcone G Clin Exp Immunol; 1989 Jun; 76(3):412-6. PubMed ID: 2546702 [TBL] [Abstract][Full Text] [Related]
10. Cell surface phenotyping and cytokine production of Epstein-Barr Virus (EBV)-transformed lymphoblastoid cell lines (LCLs). Wroblewski JM; Copple A; Batson LP; Landers CD; Yannelli JR J Immunol Methods; 2002 Jun; 264(1-2):19-28. PubMed ID: 12191505 [TBL] [Abstract][Full Text] [Related]
11. Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection. Tsuge I; Morishima T; Kimura H; Kuzushima K; Matsuoka H J Med Virol; 2001 Jun; 64(2):141-8. PubMed ID: 11360246 [TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus-transformed human B lymphocytes produce natural antibodies to histones. Garzelli C; Incaprera M; Bazzichi A; Manunta M; Rognini F; Falcone G Immunol Lett; 1994 Mar; 39(3):277-82. PubMed ID: 7518420 [TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr-virus-transformed lymphoblastoid cell lines derived from patients with X-linked agammaglobulinaemia and Wiskott-Aldrich syndrome: responses to B cell growth and differentiation factors. Lau YL; Shields JG; Levinsky RJ; Callard RE Clin Exp Immunol; 1989 Feb; 75(2):190-5. PubMed ID: 2539277 [TBL] [Abstract][Full Text] [Related]
14. Interleukin 15-mediated induction of cytotoxic effector cells capable of eliminating Epstein-Barr virus-transformed/immortalized lymphocytes in culture. Sharif-Askari E; Fawaz LM; Tran P; Ahmad A; Menezes J J Natl Cancer Inst; 2001 Nov; 93(22):1724-32. PubMed ID: 11717333 [TBL] [Abstract][Full Text] [Related]
15. Production of human monoclonal antibodies by the epstein-barr virus method. Steinitz M Methods Mol Biol; 2014; 1060():111-22. PubMed ID: 24037838 [TBL] [Abstract][Full Text] [Related]
16. Human immune responses to synthetic peptides from the Epstein-Barr nuclear antigen. Rhodes G; Carson DA; Valbracht J; Houghten R; Vaughan JH J Immunol; 1985 Jan; 134(1):211-6. PubMed ID: 2981091 [TBL] [Abstract][Full Text] [Related]
17. Spontaneously proliferating human B lymphocytes make autoantibodies. Allaway GP; Srinivasappa J; Miller FW; Prabhakar BS; Notkins AL J Infect Dis; 1988 May; 157(5):968-72. PubMed ID: 2834468 [TBL] [Abstract][Full Text] [Related]
18. Establishment of EBV-Infected Lymphoblastoid Cell Lines. Nagy N Methods Mol Biol; 2017; 1532():57-64. PubMed ID: 27873266 [TBL] [Abstract][Full Text] [Related]
19. Continuous production of monoclonal rheumatoid factor by EBV-transformed lymphocytes. Steinitz M; Izak G; Cohen S; Ehrenfeld M; Flechner I Nature; 1980 Oct; 287(5781):443-5. PubMed ID: 6253801 [TBL] [Abstract][Full Text] [Related]
20. Methylation status of the Epstein-Barr virus (EBV) BamHI W latent cycle promoter and promoter activity: analysis with novel EBV-positive Burkitt and lymphoblastoid cell lines. Hutchings IA; Tierney RJ; Kelly GL; Stylianou J; Rickinson AB; Bell AI J Virol; 2006 Nov; 80(21):10700-11. PubMed ID: 16920819 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]